IGMS250117C20000
- 0.50
- 0.000.00%
IGM Biosciences Newsroom
IGM Biosciences Analyst Ratings
BofA Securities Initiates IGM Biosciences(IGMS.US) With Hold Rating
Bank of America Securities Sticks to Their Hold Rating for IGM Biosciences (IGMS)
JPMorgan Upgrades IGM Biosciences to Neutral From Underweight
IGM Biosciences IGMS -65% Workforce & Pipeline Reduction; Senseonics SENS +76% Preliminary Revenue
J.P. Morgan Upgrades IGM Biosciences(IGMS.US) to Hold Rating
IGM Biosciences IGMS Development Halt; Precision BioSciences DTIL Phase 1/2 Data
IGM Bio Plunges as Wall Street Downgrades on Portfolio Shakeup
Crude Oil Surges 3%; Delta Air Lines Posts Better-Than-Expected Earnings
Top Midday Decliners
IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce
Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $2
Stifel Downgrades IGM Biosciences to Hold, Lowers Price Target to $2.5
Jefferies Downgrades IGM Biosciences to Hold From Buy, $2 Price Target; Shares Plunge
Dow Dips 500 Points; US Economy Adds 256,000 Jobs In December
Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)
Express News | IGM Biosciences Shares Down 69% at $1.92 Premarket After Co to Discontinue Development of Autoimmune Drugs
12 Health Care Stocks Moving In Friday's Pre-Market Session
US Stocks To Open On A Tentative Note As Traders Remain Cautious Ahead Of Friday's Crucial Jobs Data
Guggenheim Downgrades IGM Biosciences(IGMS.US) to Hold Rating